Accelerating Therapeutics for Opportunities in Medicine (ATOM)

The Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium is a 503(c)(3) public-private partnership whose mission is to transform drug discovery by accelerating the development of more effective therapies for patients.

In June 2016, GlaxoSmithKline, the Department of Energy (through Lawrence Livermore National Laboratory), and NCI (through Frederick National Laboratory for Cancer Research) announced their intent to create the ATOM partnership as one of the Cancer Moonshot℠ task forces, with funding support under the 21st Century Cures Act.

Today, ATOM is comprised of a partnership between:

ATOM models and software are available on the ATOM Modeling PipeLine (AMPL), an open source, modular, extensible software pipeline for building and sharing models to advance in silico drug discovery.

ATOM capabilities are available to the public on the capabilities page, github, and the Predictive Oncology Model and Data Clearinghouse (MoDaC).

More information on ATOM is available on the ATOM Consortium website and the Frederick National Laboratory for Cancer Research website.

Updated: